Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 5Phase NA 2Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 2Glioblastoma 2Stomach Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Head and Neck Carcinoma of Unknown Primary 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Gastrointestinal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Ependymoma 1Central Nervous System Neoplasms 1Astrocytoma 1

Interventions

Nivolumab 9pembrolizumab 6Ipilimumab 5Magnetic Resonance Spectroscopy 3resiquimod 2encorafenib 2binimetinib 2aldesleukin 2Oncolytic Virotherapy 2MART-1 Antigen 2Interleukin-2 2Cyclophosphamide 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1fludarabine phosphate 1fludarabine 1durvalumab 1clevudine 1cemiplimab 1avelumab 1Specimen Handling 1Sentinel Lymph Node Biopsy 1S 28463 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Melanoma × Radiation × Clear all
NCT04581382 2025-07-10

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

Mayo Clinic

Phase EARLY_PHASE1 Completed
18 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡